Chapter 107 - Cutaneous Melanoma

Abstract

The management of cutaneous melanoma is becoming more complex on the one hand, but decisions are now based more on evidence from clinical trials. The decision algorithm in this chapter is based on the results of contemporary clinical trials, the updated melanoma staging criteria and peer-reviewed melanoma guidelines from NCCN and ASCO. The availability of new systemic agents –both targeted therapies for patients with bRAF mutation metastases) and checkpoint inhibitors (anti-PD1, anti-PDL1 and anti-CTLA4 drugs) should be incorporated into the management of melanoma patients with both Stage III (as adjuvant therapy) and Stage IV melanoma.